Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRGX NASDAQ:ENGN NASDAQ:GNFT NASDAQ:PDSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRGXCARGO Therapeutics$4.47$4.47$3.00▼$25.45$216.17M0.31.73 million shsN/AENGNenGene$4.87+1.5%$3.86$2.65▼$11.00$236.11M-0.3954,855 shs226,009 shsGNFTGENFIT$3.93+2.2%$3.91$2.55▼$6.42$200.01M1.163,652 shs881 shsPDSBPDS Biotechnology$1.30+4.0%$1.21$0.85▼$4.29$58.29M1.15534,427 shs552,549 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRGXCARGO Therapeutics0.00%0.00%-0.22%-1.97%-74.82%ENGNenGene+1.46%+12.21%+27.49%+34.53%-27.53%GNFTGENFIT+2.05%-4.38%+3.56%-11.50%-4.27%PDSBPDS Biotechnology+4.00%+1.56%+16.07%-16.67%-56.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRGXCARGO Therapeutics2.1177 of 5 stars2.90.00.00.02.01.71.3ENGNenGene3.1945 of 5 stars3.55.00.00.01.22.50.6GNFTGENFIT2.3261 of 5 stars3.54.00.00.02.80.00.0PDSBPDS Biotechnology2.6367 of 5 stars3.55.00.00.02.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRGXCARGO Therapeutics 1.86Reduce$15.40244.52% UpsideENGNenGene 3.00Buy$23.29378.15% UpsideGNFTGENFIT 3.00Buy$9.00129.30% UpsidePDSBPDS Biotechnology 3.00Buy$10.00669.23% UpsideCurrent Analyst Ratings BreakdownLatest PDSB, ENGN, GNFT, and CRGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025GNFTGENFITHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.007/8/2025CRGXCARGO TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$3.70 ➝ $5.007/1/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/11/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRGXCARGO TherapeuticsN/AN/AN/AN/A$4.91 per shareN/AENGNenGeneN/AN/AN/AN/A$5.35 per shareN/AGNFTGENFIT$76.77M2.56$0.07 per share57.19$1.50 per share2.62PDSBPDS BiotechnologyN/AN/AN/AN/A$0.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRGXCARGO Therapeutics-$167.50M-$4.64N/AN/AN/AN/A-43.21%-37.26%11/11/2025 (Estimated)ENGNenGene-$55.14M-$1.65N/AN/AN/AN/A-32.60%-28.26%9/10/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A9/22/2025 (Estimated)PDSBPDS Biotechnology-$37.61M-$0.92N/AN/AN/AN/A-184.56%-79.00%11/13/2025 (Estimated)Latest PDSB, ENGN, GNFT, and CRGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/10/2025Q3 2025ENGNenGene-$0.5084N/AN/AN/AN/AN/A8/13/2025Q2 2025PDSBPDS Biotechnology-$0.24-$0.21+$0.03-$0.21N/AN/A6/10/2025Q2 2025ENGNenGene-$0.4768-$0.51-$0.0332-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRGXCARGO TherapeuticsN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRGXCARGO TherapeuticsN/A12.3712.37ENGNenGene0.0912.6612.66GNFTGENFIT0.081.231.23PDSBPDS Biotechnology0.812.922.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRGXCARGO Therapeutics93.16%ENGNenGene64.16%GNFTGENFIT2.24%PDSBPDS Biotechnology26.84%Insider OwnershipCompanyInsider OwnershipCRGXCARGO Therapeutics2.92%ENGNenGene10.40%GNFTGENFIT4.20%PDSBPDS Biotechnology9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRGXCARGO Therapeutics11648.36 million46.95 millionN/AENGNenGene3151.10 million45.79 millionN/AGNFTGENFIT12050.00 million47.90 millionNot OptionablePDSBPDS Biotechnology2046.63 million42.34 millionOptionablePDSB, ENGN, GNFT, and CRGX HeadlinesRecent News About These CompaniesArmistice Capital LLC Acquires Shares of 4,419,000 PDS Biotechnology Corporation $PDSBSeptember 2 at 8:33 AM | marketbeat.comPDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2 at 8:00 AM | globenewswire.comPDS Biotechnology Announces Promising Phase 2 Trial ResultsAugust 25, 2025 | msn.comPDS Biotechnology announces data from its VERSATILE-002 Phase 2 trialAugust 25, 2025 | msn.comPDS Biotechnology stock rises after announcing promising cancer trial dataAugust 25, 2025 | za.investing.comPDS Biotechnology Reports 39.3-Month Median Overall Survival in VERSATILE-002 Trial for HPV16-Positive Head and Neck CancerAugust 25, 2025 | quiverquant.comQPDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck CancerAugust 25, 2025 | manilatimes.netMPDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck CancerAugust 25, 2025 | globenewswire.comQ3 EPS Forecast for PDS Biotechnology Boosted by AnalystAugust 17, 2025 | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) Announces Quarterly Earnings ResultsAugust 15, 2025 | marketbeat.comBiotech Stocks Rally as Oncology Market Targets $866B by 2034August 14, 2025 | prnewswire.co.ukPPDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | insidermonkey.comPDS Biotechnology Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comPDS Biotechnology reports Q2 EPS (21c), consensus (23c)August 13, 2025 | msn.comPDS Biotechnology: Q2 Earnings SnapshotAugust 13, 2025 | stamfordadvocate.comSPDSB Loss Improves as Costs DropAugust 13, 2025 | aol.comAPDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs UpdateAugust 13, 2025 | globenewswire.comInsights into PDS Biotechnology's Upcoming EarningsAugust 12, 2025 | benzinga.comPDS Biotechnology (PDSB) Projected to Post Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comPDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePDSB, ENGN, GNFT, and CRGX Company DescriptionsCARGO Therapeutics NASDAQ:CRGX$4.47 0.00 (0.00%) As of 08/19/2025CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.enGene NASDAQ:ENGN$4.87 +0.07 (+1.46%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$5.08 +0.21 (+4.21%) As of 09/3/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.GENFIT NASDAQ:GNFT$3.82 -0.02 (-0.49%) As of 09/3/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.PDS Biotechnology NASDAQ:PDSB$1.30 +0.05 (+4.00%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$1.21 -0.09 (-6.92%) As of 09/3/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
